In the 2022 American Society of Clinical Oncology (ASCO) meeting, SAF-189 s, a next-generation ALK inhibitor, achieved excellent results and was well tolerated in patients with advanced, ALK-positive NSCLC, with a DCR of 100% in both the ALK inhibitor group and the ALK inhibitor-naïve group. This evidence concerns the gene ALK and non-small cell lung carcinoma.